marginal zone lymphoma
marginal zone lymphoma
Explore linked clinical trials. Standard reference: MONDO:001760471 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-10-09 | NCT06026319 | |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04542824 | |
| A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT05006716 | |
| Preliminary Assessment of [18F]BL40 in PET/CT Scans | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-10-01 | NCT06224309 | |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, gastric mucosa-associated lymphoid tissue lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | Recruiting | Phase 2 | 2026-09-29 | NCT07583810 | |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2026-09-28 | NCT06350318 | |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05100862 | |
| Epco, Zanu, Ritux for R/R FL or MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-25 | NCT06563596 | |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-09-25 | NCT05783596 | |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2026-09-21 | NCT05296070 | |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm | Enrolling by invitation | Phase 1 | 2026-09-14 | NCT07168486 | |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-09-09 | NCT07225439 | |
| Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, cardiovascular disorder, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-09 | NCT05326308 | |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04680052 | |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, primary central nervous system lymphoma, vascular disorder, vascular hemostatic disease, viral infectious disease | Active, not recruiting | Phase 1 | 2026-08-27 | NCT04464200 | |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, Waldenstrom macroglobulinemia, cardiovascular disorder, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05294731 | |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 1 | 2026-08-21 | NCT03884998 | |
| Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Not stated | 2026-08-20 | NCT07777120 | |
| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2026-08-20 | NCT04792502 | |
| HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 2 | 2026-08-12 | NCT06792825 | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Tumor Virus Infections, Waldenstrom macroglobulinemia, cardiovascular disorder, follicular lymphoma, hairy cell leukemia, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, leukemia, lymphatic system disorder, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease, viral infectious disease | Recruiting | Phase 1 | 2026-08-12 | NCT06340737 | |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Richter transformation, histiocytosis, interdigitating dendritic cell sarcoma, lymphatic system disorder, malignant histiocytosis, marginal zone lymphoma, neoplasm | Not yet recruiting | Phase 2 | 2026-08-06 | NCT07744750 | |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, acute biphenotypic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, mixed phenotype acute leukemia, neoplasm, non-Hodgkin lymphoma, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-08-06 | NCT06533579 | |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma, viral infectious disease | Recruiting | Phase 1 | 2026-08-06 | NCT05990465 | |
| Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | marginal zone lymphoma | Not yet recruiting | Phase 2 | 2026-07-29 | NCT07459608 |